Immunovant, Inc. Units
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch IMVTU and buy or sell other stocks, ETFs, and their options commission-free!About IMVTU
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor.
CEOEric Venker, MD, PharmD
CEOEric Venker, MD, PharmD
Employees362
Employees362
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2018
Founded2018
Employees362
Employees362
IMVTU Key Statistics
Market cap5.28B
Market cap5.28B
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume183.20
Average volume183.20
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$33.30
52 Week high$33.30
52 Week low$10.32
52 Week low$10.32
Stock Snapshot
As of today, Immunovant, Inc. Units(IMVTU) shares are valued at $30.28. The company's market cap stands at 5.28B.
During the trading day, Immunovant, Inc. Units(IMVTU) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading activity shows a volume of 0, compared to an average daily volume of 183.2.
Over the past 52 weeks, Immunovant, Inc. Units(IMVTU) stock has traded between a high of $33.30 and a low of $10.32.
Over the past 52 weeks, Immunovant, Inc. Units(IMVTU) stock has traded between a high of $33.30 and a low of $10.32.